Evidence map›Paper›PMID 40356937›Full record

ArticleSouthern African journal of HIV medicine2025

Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ART.

Kirusha Naidoo, Richard J Lessells, Jienchi Dorward, Mahomed Y S Moosa, Yukteshwar Sookrajh, Pravi Moodley, Paul K Drain, Nigel Garrett

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Southern African journal of HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kirusha NaidooDepartment of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.ORCID https://orcid.org/0009-0002-8835-5190
Richard J LessellsDepartment of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.ORCID https://orcid.org/0000-0003-0926-710X
Jienchi DorwardDepartment of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.ORCID https://orcid.org/0000-0001-6072-1430
Mahomed Y S MoosaDepartment of Infectious Diseases, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.ORCID https://orcid.org/0000-0001-6191-4023
Yukteshwar SookrajheThekwini Municipality Health Unit, Durban, South Africa.ORCID https://orcid.org/0000-0001-9029-5153
Pravi MoodleyDepartment of Virology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.ORCID https://orcid.org/0000-0002-9946-8783
Paul K DrainDepartment of Epidemiology, University of Washington, Seattle, Washington, United States of America.ORCID https://orcid.org/0000-0002-9569-4097
Nigel GarrettDepartment of HIV Vaccines and Pathogenesis, Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.ORCID https://orcid.org/0000-0002-4530-234X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The integrase strand transfer inhibitor, dolutegravir (DTG), is widely used in first- and second-line antiretroviral therapy (ART) regimens in South Africa. We describe an adult with virological failure on second-line tenofovir/lamivudine/dolutegravir (TLD2) and rapid emergence of DTG resistance within 3 months, while receiving rifapentine-based tuberculosis preventive therapy.

Indexed as

dolutegravirdolutegravir resistancedrug-drug interactiondrug resistancerifapentine

Identifiers

PMID40356937
PMCPMC12067546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.